9th World Congress on BA/BE Studies and Biowaivers
| Date: | 17-Jul-17 to 18-Jul-17 |
| Location: | Novotel Melbourne St Kilda / Melbourne / Australia |
| Category: | Conferences & Trade Fairs |
It’s time to announce “9th World Congress on BA/BE Studies and Biowaivers” held July 17-19, 2017 at Melbourne, Australia. Bioequivalence Congress is a 3-day event offering the Exhibition, at venue to showcase the research and development on emerging technologies and have wider sessions involving Keynote presentation, Oral, YRF ( student presentation), poster, e-poster presentations. This is an excellent platform to intensify collaborations for Professionals Scientific Experts and Industrial Delegates for Pharma field knowledge seekers.
The global generic drugs market 2016 report forecasts patent expiry of drugs worth $150 billion by 2020, which a key growth driver for top-selling drugs as well as new, inexpensive generic drugs. Patent expiry of a branded drug results in the introduction of inexpensive generic drugs in the market. Branded drugs with sales of up to $135 billion expired by the end of 2015, offering pharmaceutical companies opportunities to capitalize on this market. The Australian pharmaceuticals industry comprises bio-medical research, biotechnology firms, originator and generic medicines companies and service-related segments including wholesaling and distribution. This sector is expected to reach $300.9 billion in 2013 and $518.5 billion in 2018, with a compound annual growth rate (CAGR) of 11.5%.
Everyone interested in the future of emerging –drugs majorly in the field drug discovery, design, drug development, pharmacokinetic research, clinical pharmacology and new therapeutic drugs on recent developments in the field of generic drug research, current challenges and possibilities in modeling a new drug involving bioavailability and bioequivalence research.
The global generic drugs market 2016 report forecasts patent expiry of drugs worth $150 billion by 2020, which a key growth driver for top-selling drugs as well as new, inexpensive generic drugs. Patent expiry of a branded drug results in the introduction of inexpensive generic drugs in the market. Branded drugs with sales of up to $135 billion expired by the end of 2015, offering pharmaceutical companies opportunities to capitalize on this market. The Australian pharmaceuticals industry comprises bio-medical research, biotechnology firms, originator and generic medicines companies and service-related segments including wholesaling and distribution. This sector is expected to reach $300.9 billion in 2013 and $518.5 billion in 2018, with a compound annual growth rate (CAGR) of 11.5%.
Everyone interested in the future of emerging –drugs majorly in the field drug discovery, design, drug development, pharmacokinetic research, clinical pharmacology and new therapeutic drugs on recent developments in the field of generic drug research, current challenges and possibilities in modeling a new drug involving bioavailability and bioequivalence research.
Exhibitors
Daisy Pearl
EIN News
provides powerful, real-time media monitoring, news aggregation & syndication services. Read the latest news about this topic. See:
